Michael Lane - 12 Feb 2026 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: Executive Vice President
Issuer ticker: IDXX
Reported as of: 12 Feb 2026
Net transaction value: -$139,086
SEC form: 4
Accepted by SEC: 17 Feb 2026, 19:30:50 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Michael Lane

Key filing fact

Michael Lane filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 17 Feb 2026.

Key facts

This page summarizes Michael Lane's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
13 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 19:30.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: -$139,086.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001740689 Primary reporting owner

Lane Michael

Relationship: Executive Vice President
Address: ONE IDEXX DRIVE, WESTBROOK
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Michael Lane
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +204
Change %: +2.9%
Price: $0.000000
Shares after: 7,357
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F1

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +220
Change %: +3%
Price: $0.000000
Shares after: 7,577
Date: 14 Feb 2026
Ownership: Direct

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +301
Change %: +4%
Price: $0.000000
Shares after: 7,878
Date: 14 Feb 2026
Ownership: Direct

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +367
Change %: +4.7%
Price: $0.000000
Shares after: 8,245
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F2

IDXX transaction

Common Stock

Tax liability

Transaction value: $139,086
Shares: -221
Change %: -2.7%
Price: $629.35
Shares after: 8,024
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F3, F4

IDXX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 592
Date: 12 Feb 2026
Ownership: by spouse
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value: $0
Shares: +5,361
Change %
Price: $0.000000
Shares after: 5,361
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,361
Exercise price: $617.20
Footnotes: F6

IDXX transaction Derivative

Incentive Stock Option (right-to-buy)

Award

Transaction value: $0
Shares: +162
Change %
Price: $0.000000
Shares after: 162
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 162
Exercise price: $617.20
Footnotes: F7

IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +1,262
Change %
Price: $0.000000
Shares after: 1,262
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,262
Exercise price
Footnotes: F8

IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +1,620
Change %
Price: $0.000000
Shares after: 1,620
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,620
Exercise price
Footnotes: F9

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -367
Change %: -25%
Price: $0.000000
Shares after: 1,101
Date: 14 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 367
Exercise price
Footnotes: F10

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -204
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 14 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 204
Exercise price
Footnotes: F11

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -220
Change %: -50%
Price: $0.000000
Shares after: 220
Date: 14 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220
Exercise price
Footnotes: F12

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -301
Change %: -33%
Price: $0.000000
Shares after: 602
Date: 14 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 301
Exercise price
Footnotes: F13

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 252.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares.

Footnote F2

Represents Restricted Stock Units ('RSU') that were granted on February 14, 2025, were deferred in accordance with the Issuer's Deferred Compensation Plan and have vested. Upon vesting, these RSUs were recorded in an account under such Plan and represents a contingent right to receive one share of Issuer common stock that is payable as soon as practicable after the reporting person's termination of employment with the Issuer.

Footnote F3

Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.

Footnote F4

Includes 367 vested but deferred RSUs.

Footnote F5

Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

Footnote F6

Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.

Footnote F7

Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.

Footnote F8

Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027.

Footnote F9

Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027.

Footnote F10

Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan.

Footnote F11

Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.

Footnote F12

Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.

Footnote F13

Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.